Missouri Attorney General Catherine Hanaway this week asked a federal court to roll back the U.S. Food and Drug Administration’s (“FDA”) recent decision to approve a new generic brand of mifepristone. The lawsuit challenges the latest FDA approval, issued on September 30, 2025, that authorizes an additional generic version of mifepristone.
“Mifepristone is sending women to the hospital with life-threatening complications, and yet drug companies continue pushing new versions of it into the market without basic medical safeguards,” said Attorney General Hanaway. “Mail-order abortion drugs are dangerous when taken without in-person care, and Missouri will not stand by while manufacturers gamble with women’s lives.”
Missouri, joined by Kansas and Idaho, is asking the Court to:
- Block the new generic mifepristone approval,
- Restore pre-2016 safety standards,
- Enjoin the mail-order distribution of abortion drugs, and
- Stop drug manufacturers and distributors from enabling violations of state law
More information about the new legal challenge can be found here.